

ABBREVIATED ACCOUNTS
FOR THE YEAR ENDED
30 JUNE 2016

MAINE PHARMA CONSULTING
LIMITED

MENZIES

MAINE PHARMA CONSULTING LIMITED

COMPANY INFORMATION

Director	N. Clapson
Registered number	06607410
Registered office	50 Stile Hall Gardens Chiswick London W4 3 BU
Accountants	Menzies LLP Chartered Accountants Centrum House 36 Station Road Egham Surrey TW20 9LF

MAINE PHARMA CONSULTING LIMITED

REGISTERED NUMBER: 06607410

ABBREVIATED BALANCE SHEET AS AT 30 JUNE 2016

	Note	£	2016 £	£	2015 £
Fixed assets					
Tangible assets	2		1,723		1,943
Current assets					
Debtors		53,980		38,247	
Cash at bank		<u>733</u>		<u>5,406</u>	
		54,713		43,653	
Creditors: amounts falling due within one year		<u>(52,918)</u>		<u>(41,431)</u>	
Net current assets			<u>1,795</u>		<u>2,222</u>
Total assets less current liabilities			<u>3,518</u>		<u>4,165</u>
Capital and reserves					
Called up share capital	4		100		100
Profit and loss account			<u>3,418</u>		<u>4,065</u>
Shareholders' funds			<u>3,518</u>		<u>4,165</u>

The director considers that the company is entitled to exemption from the requirement to have an audit under the provisions of section 477 of the Companies Act 2006 ("the Act") and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Act.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and for preparing financial statements which give a true and fair view of the state of affairs of the company as at 30 June 2016 and of its profit for the year in accordance with the requirements of sections 394 and 395 of the Act and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The abbreviated accounts, which have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006, were approved and authorised for issue by the board and were signed on its behalf on 19 May 2017.

N. Clapson
Director

The notes on page 2 form part of these financial statements.

MAINE PHARMA CONSULTING LIMITED

NOTES TO THE ABBREVIATED ACCOUNTS FOR THE YEAR ENDED 30 JUNE 2016

1. Accounting Policies

1.1 Basis of preparation of financial statements

The full financial statements, from which these abbreviated accounts have been extracted, have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective January 2015).

At the balance sheet date there was an accounting surplus of £,3518 (2015 £4,165). Notwithstanding the surplus in the previous period, the financial statements have been prepared on a going concern basis as the directors is confident that sufficient funding will be available to enable the company to continue to trade for the foreseeable future.

1.2 Turnover

Turnover comprises revenue recognised by the company in respect of goods and services supplied during the year, exclusive of Value Added Tax and trade discounts.

2. Tangible fixed assets

	£
Cost	
At 1 July 2015	7,675
Additions	<u>1,100</u>
At 30 June 2016	<u>8,775</u>
Depreciation	
At 1 July 2015	5,732
Charge for the year	<u>1,320</u>
At 30 June 2016	<u>7,052</u>
Net book value	
At 30 June 2016	<u><u>1,723</u></u>
At 30 June 2015	<u><u>1,943</u></u>

3. Director's benefits: advances, credit and guarantees

At the balance sheet date Mr N Clapson owed the company an amount of £34,049 (2015 : 27,398)

4. Share capital

	2016 £	2015 £
Allotted, called up and fully paid		
100 Ordinary shares of £1 each	<u><u>100</u></u>	<u><u>100</u></u>

